Clinical Trials Logo

NAFLD clinical trials

View clinical trials related to NAFLD.

Filter by:

NCT ID: NCT04187339 Completed - Obesity Clinical Trials

Study of NGM395 in Adult Participants

Start date: February 13, 2020
Phase: Phase 1
Study type: Interventional

Study of NGM395 in adult participants.

NCT ID: NCT04186260 Recruiting - NAFLD Clinical Trials

A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men

Start date: February 5, 2024
Phase: N/A
Study type: Interventional

Using a small Randomized Controlled Trial (RCT) study design, PNPLA3 risk allele carriers (CG/GG genotype) with NAFLD, will be assigned 2:1 to a tailored NAFLD-specific weight loss intervention compared to a wait-list control group.

NCT ID: NCT04146636 Completed - NAFLD Clinical Trials

Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients (IMPROVE Study)

IMPROVE
Start date: December 9, 2019
Phase: N/A
Study type: Interventional

The main objective is to determine the performance of the simple eLIFT blood test for advanced liver fibrosis screening in NAFLD and/or alcoholic patients in primary care.

NCT ID: NCT04127370 Not yet recruiting - Clinical trials for Bariatric Surgery Candidate

The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease

Start date: November 1, 2019
Phase: N/A
Study type: Interventional

The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease

NCT ID: NCT04084925 Completed - NAFLD Clinical Trials

HOMA-IR as a Screening Test in NAFLD

Start date: December 1, 2017
Phase:
Study type: Observational

The aim of this study is to evaluate the role of HOMA-IR in diagnosis of NAFLD in patients with type 2 DM.

NCT ID: NCT04081571 Recruiting - Insulin Resistance Clinical Trials

Prevalence of NAFLD and Correlation With Its Main Risk Factors Among Egyptian

Start date: April 1, 2019
Phase:
Study type: Observational

Getting a rough indicator about the prevalence of different grade of severity of NAFLD (NASH & liver fibrosis), and Correlate the severity of fatty liver with different serological risk factors of metabolic syndrome and diseases progression as well as the prevalence of hepatocellular carcinoma related to NAFLD with the use of ; nutritional assessment designed and conducted by the investigators in this research, simple blood test (lipid profile and blood sugar), and easy cheap non-invasive radiological tool as screening to predict NASH.

NCT ID: NCT04073407 Terminated - NAFLD Clinical Trials

Study of the Safety and Tolerability of AXA1957 in Adolescent Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

Start date: July 27, 2019
Phase: N/A
Study type: Interventional

This is a randomized, single blind study to determine whether AXA1957, a novel composition of amino acids, is safe and well tolerated. Subjects will be adolescents with non-alcoholic fatty liver disease (NAFLD), and it will also examine liver biology using blood tests and magnetic resonance imaging (MRI).

NCT ID: NCT04073368 Completed - NAFLD Clinical Trials

Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

Start date: December 3, 2018
Phase: N/A
Study type: Interventional

This is a randomized, single blind study to determine whether AXA1125 or AXA1957, novel compositions of amino acids, are safe and well tolerated. Subjects have non-alcoholic fatty liver disease (NAFLD) and the study will also examine liver biology using blood tests and magnetic resonance imaging (MRI).

NCT ID: NCT04036357 Recruiting - Clinical trials for Cardiovascular Diseases

Liver Damage and Cardiometabolic Disorders in NAFLD

PLINIO
Start date: November 2011
Phase:
Study type: Observational

Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.

NCT ID: NCT04006145 Completed - NAFLD Clinical Trials

A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH

Start date: June 6, 2019
Phase: Phase 2
Study type: Interventional

Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)